Piperacillin tazobactum is an extended spectrum pencillin belonging to uriedopencillin class used in the management of polybacterial infections. A 37 year old male patient admitted to the hospital with the chief complaints of breathlessness since 8 days and cough with expectoration since 2 days. The patient was initially managed with nebulization and bronchodilator therapy with subsequent administration of Piperacillin Tazobactum (4.5 gm) antibiotic to treat underlying infection. The patient complained the development of pruritis and red color skin rashes over the back of neck after receiving first dose of Piperacillin Tazobactum, the antibiotic was stopped and supportive treatment with antihistamine and corticosteroid was provided to treat allergic reaction. The symptoms were healed and patient condition was improved on discharge. The suspected drug reaction with Piperacillin Tazobactum was found to have "probable" causal relationship through Naranjo causality assessment and pose "moderate" severity as assessed through Hartwig's Severity scale. The report suggests close monitoring of Piperacillin-Tazobactam usage among patient population.
INTRODUCTION
Uriedopencillin class of antibiotics are also named as antipseudomonal penicillins. Among these class of drugs piperacillin is more potent and pose superior action against Klebshiella and is effective in neutropenic/ immune compromised patients having serious gram-negative infections and in burns. 1 Pharmacokinetics of Piperacillin matches with Tazobactum, which is used in severe infections like peritonitis, pelvic/ urinary/respiratory infections. However, this combination is not effective against piperacillin-resistant Pseudomonas. A dose of 4-12 g/day is required for mild infections and in case of severe infections a higher dose is required (12-24g/day). The combination of Piperacillin-Tazobactum was effective against a range of gram-positive and and gram negative bacterial infections. 1, 2 The poor solubility of the piperacillin and tazobactam co-formulation means that intravenous administration is preferred because of the large volume of fluid required for solubilization (10-20 ml water for injection). Administration is recommended by the product information as a slow A recent systematic study review stated that a variety of adverse reactions has been reported with the piperacillin-tazobactam like hemolytic anemia, bone marrow suppression diseases (such as neutropenia and thrombocytopenia), type 1 hypersensitivity and acute delirium. 4, 5 A array of adverse reactions can precipitate within minutes after the hours of exposure to a drug which are of type 'A' or "Augmented' in nature and usually have a low mortality. 6 Others pencillin class of drugs are not readily predictable due to high mortality risk (Type 'B' or 'Bizarre'). 6 In our case study we describe an unusual case of an immediate reaction to Piperacillin-Tazobactam.
CASE REPORT
A 37 year old male patient was presented to the outpatient clinic of a teaching hospital with the chief complaints of breathlessness since eight days and coughs with expectoration since two days and was later hospitalized. The history of presenting complaints reveals that the patient was apparently alright before he developed breathlessness which was sudden in onset and progressive in nature a week ago and subsequently complaints of cough with expectoration since last two days. The sputum was white in color, non-foul smelling without any blood stain. The patient past medical/medication assessment does not reveal any other concurrent illness or co morbidity. 
In the current case, the patient was hospitalized with the chief complaints of breathlessness and cough with expectoration with an underlying infection evident from laboratory investigation. The patient condition was indicative for the use of anti microbial therapy. Piperacillin Tazobactum 4.5 gm was prescribed twice daily. After around five hours of receiving first dose of antimicrobial therapy, the patient developed pruritic red colour skin rash over the back of neck prompting the physician to withdraw the anti microbial from patient medication list as a probable suspected drug for the developed adverse skin reaction. The patient was managed symptomatically using antihistamine Table 2 : Severity Assessment of Suspected ADR using Hartwig's Scale.
Level Description 1
An ADR occurred but required no change in treatment with the suspected drug.
2
The ADR required that treatment with the suspected drug be held, discontinued, or otherwise changed. No antidote or other treatment requirement was required. No increase in length of stay (LOS)
3
The ADR required that treatment with the suspected drug be held, discontinued, or otherwise changed. And/ or An Antidote or other treatment was required. No increase in length of stay (LOS) symptom and the patient condition gradually improved without any fresh complaint and was fully recovered at the time of discharge.
There were report of mild to moderate adverse effects with the use of piperacillin tazobactum that includes diarrhea, rash, erythema, pruritis, allergic reactions, urticaria, superinfection, phlebitis, dyspepsia and insomnia. Serious and occasionally fatal hypersensitivity (Anaphylactic/ anaphylactoid) reactions (Including shock) have also been described to the use of piperacillin tazobactum in patients. Patients with history of sensitivity to penicillin, cephalosporin, or carbapenem or a history of sensitivity to multiple allergens are on the higher risk of incidence. The drug was discontinued in 3.2% of patients due to dermatologic adverse effects [Rash and pruritus], gastrointestinal effects, allergic effects and 11%
of patients with nosocomial pneumonia as reported by clinical trial data. A careful investigation should be carried out in patients concerning previous hypersensitivity and the drug should be discontinued or replaced if reported with an allergic reaction incidence.
The literature provides enough evidence to suspect piperacillin tazobactum might have caused the allergic reaction, hence the suspected drug was subjected for causality assessment using Naranjo scale [ Table 1 ] and Hartwig's scale was use to assess the severity of the adverse reaction. [ Table 2 ]. A total score of "7" was obtained through naranjo assessment, which indicates that there is a probability that the adverse reaction is caused due to the suspected drug itself. The severity of the ADR falls under level 4 as a "moderate" severe reaction as per hartwig's assessment.
CONCLUSION
The observed suspected Adverse drug reaction [ADR] was found to have "Probable" causal relationship to the use of "Piperacillin tazobactum" as per naranjo causality assessment and falls under "Moderate" severe reaction category as per hartwig's assessment. The case report suggests close monitoring of piperacillin-tazobactum usage among patient population for the possible occurrence of ADR.
